🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Researchers in immune imaging! Submit to our Special Collection: Imaging in Immunotherapy Topics include: 🧬 Molecular imaging 📡 Image-guided drug delivery 🧫 Real-time immune monitoring 📅 Deadline: June 2025 🔗bit.ly/3GS8t6J

Can blood sugar and lipids influence immune dysfunction in Behçet’s disease? New study says yes. ➡️ High glucose & TAG levels drive Th1, CD8+ T cell, & B cell activation. Read how metabolism shapes immunity: bit.ly/44HA2t9 #Autoimmunity #Inflammation

Don't miss your last chance to get involved in Immunotherapy Advances Journal's upcoming collection on B cell and immune regulation 🧫 Topics include phenotype, function, and mechanism of regulatory B cells and clinical studies. Submit by June 2025: oxford.ly/4kligQR

Immunotherapy Advances welcomes rigorous research spanning discovery, preclinical models & clinical trials - including negative results that advance immune-mechanistic insights. Submit your work today: bit.ly/3KkrdJr

A phase 3 study in Japanese PID patients shows 20% subcutaneous immunoglobulin (Ig20Gly) given weekly or biweekly maintains protective IgG levels, the key antibody for infection defence - while showing a strong safety profile. Read more: bit.ly/3HnCGdN

🧬 New in Immunotherapy Advances: CTLA-4 - two paths to anti-tumour immunity? This review explores dual mechanisms of anti-CTLA-4 therapy and the emerging role of sCTLA-4 in shaping cancer immunotherapy. A must-read for checkpoint inhibitor research: bit.ly/4k6jcZj

Peanut oral immunotherapy is showing promise in clinical trials, offering hope for safer desensitization in peanut-allergic individuals. But risks like serious reactions and patient anxiety remain. Optimized protocols are key. 🌰🧬 🔗 bit.ly/43Aqazf #Immunotherapy

Attending the 3rd OCION Annual Symposium hosted by @oxfordcancer on 13 June in Oxford? 🚀 Don’t miss the chance to share your work with a wider audience - consider submitting your research to Immunotherapy Advances! 📢 bit.ly/3KkrdJr #OCION2025 #CancerResearch

Whether discovery research, preclinical models, or clinical studies – Immunotherapy Advances welcomes your immunotherapy manuscript! 🧬🧪 Publish Open Access with expert editorial support. Submit today: bit.ly/3KkrdJr #Immunotherapy #CancerResearch #OpenAccess

🚨 Last chance to submit! The Imaging in Immunotherapy Special Collection closes end of June! Got cutting-edge research on molecular imaging or image-guided drug delivery? Submit now and get extra promotion. 📩 More info//bit.ly/4j8c265 #Immunotherapy

Durvalumab after chemoradiotherapy boosts survival in stage III NSCLC patients. Real-world UK data supports PACIFIC trial findings. Treatment tolerance matters! Explore here: bit.ly/43OIkyt #Immunotherapy #CancerResearch

Looking to publish your immunotherapy research? 🔬✨ We welcome rigorous studies from discovery to clinical trials, human or animal, positive or negative results - all with a translational focus. Fully Open Access & global reach! Submit today: bit.ly/3WmPhl3

🎉 The 2025 Oxford Cancer Immuno-Oncology Network Symposium is in full swing! Oxford Cancer If you're attending, swing by our stand to chat all things Immunotherapy Advances - we'd love to connect!

⏳ Last chance to submit! Our special collection on Imaging in Immunotherapy closes end of June 2025. Don’t miss the opportunity to feature your research on molecular imaging, drug delivery & immune monitoring. 📢 Submit now: bit.ly/4j8c265

🧪 New in Immunotherapy Advances: A scalable 3D in vitro model mimics CTL exhaustion, enabling deeper insight into T cell suppression and therapeutic response. Essential reading for anyone developing CTL-targeting immunotherapies. 🔗 bit.ly/4e1appC #Immunotherapy

June is #MyastheniaAwarenessMonth 🧠 #MAM2025 Regulatory B cells (Bregs) are key to immune balance, but in Myasthenia Gravis & other autoimmune diseases, their function falters. This review maps Breg heterogeneity & therapeutic potential. 📖 bit.ly/4n1l3AW

It’s #CervicalScreeningAwarenessWeek 🎗️ Tumour-reactive plasma cells fight HPV-driven cancers by making antibodies against HPV E2 proteins - offering new hope for personalized immunotherapy. 📖 bit.ly/3SVZsMC

🚨 Submit to the Immunotherapies for Inborn Errors of Immunity special collection! We’re looking for research & reviews on targeted treatments, molecular pathways, and novel therapies for genetic immune disorders. 🗓️ Deadline: Sept 2025 🔗 bit.ly/45mr1m8

🔍 What do we really know about DC3s in solid tumors? This new article explores the phenotype, function & impact of DC3s across cancers - highlighting their complex roles in both immunity & immunosuppression. 📖 Read it now: bit.ly/3T2blRg #Immunotherapy

🚨 Researchers at over 120 UK institutions can publish open access for free in Immunotherapy Advances! No APCs, just impactful immunotherapy research shared with the world. 🌐 #OpenScience 🔗Check eligibility here: bit.ly/4no9OTy